Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 59
Filter
1.
J Gynecol Obstet Hum Reprod ; 52(9): 102653, 2023 Nov.
Article in English | MEDLINE | ID: mdl-37634700

ABSTRACT

BACKGROUND: Grade 1 breast cancer represents the lowest grade of invasive breast cancer and is associated with a low risk of recurrence and distant metastasis. However, when grade 1 breast cancer is associated with lymph node involvement, the prognosis may be worse than that of grade 1 breast cancer without lymph node involvement. METHOD: The study population included all patients who were managed in our institution between January 1, 2007 and December 31, 2013 for grade 1 breast cancer . We compared patients who had lymph node involvement to those who had no lymph node involvement. RESULTS: During the study period 291 grade 1 carcinomas were included of which 23% had associated positive lymph node involvement. Overall survival did not differ significantly between patients without lymph node involvement and those with lymph node involvement, nor was there a significant difference in the risk of local recurrence free survival. However, a significant difference was found in survival without distant metastasis with a significant level of a p at 0.029. CONCLUSION: Our findings confirm that tumor size and LVSI are strong predictors of axillary lymph node involvement, which is a key determinant of distant metastasis-free survival.


Subject(s)
Breast Neoplasms , Humans , Female , Breast Neoplasms/pathology , Lymphatic Metastasis/pathology , Axilla/pathology , Lymph Nodes/pathology , Prognosis
2.
J Gynecol Obstet Hum Reprod ; 51(10): 102481, 2022 Dec.
Article in English | MEDLINE | ID: mdl-36208828

ABSTRACT

OBJECTIVES: We performed a systematic review in order to describe the clinical presentation, therapeutic management and outcomes of malignant myoepitelioma of the breast. SEARCH STRATEGY: A systematic search of MEDLINE and EMBASE references from January 1980 to Marsh 2020 was performed. We included articles that reported cases of malignant breast myoepithelioma. Data from eligible studies were independently extracted onto standardized forms by two reviewers. RESULTS: 31 articles including 47 cases of malignant breast myoepithelioma and 3 other unpublished cases managed in our establishment were included in this systematic review. The average age at diagnosis was 60.7 years old [range 30-81]. The average size of the tumor was 46mm [range 10 -230]. 30 patients had a partial mastectomy and 18 a total mastectomy. Only 15% of patient (7/48) had an axillary sentinel lymph node biopsy of whom one was positive. 33% of patients (16/48) had an axillary lymph node dissection which was positive for one patient. 19% (n=9) had adjuvant radiotherapy and 15% (n=7) had adjuvant chemotherapy. 33% (n=10) of patients with partial mastectomy had at least one recurrence, versus 5.5% (n=1) after a total mastectomy. The average time between the diagnosis and the first recurrence was 25.4 months [range: 1-50]. 64% (n=7) had a second partial mastectomy and only 18% (n=2) had a total mastectomy. 27% of patient had chemotherapy after their first recurrence and 27% had radiotherapy if it was not received in first line treatment. 40% (n=4/10) of patients with partial mastectomy who recurred have had at least 2 breast recurrences. 28% (n=14) of all patients had distant metastases. 20% of patients (n=10) died whose 80% (n=8) had distant metastatic disease. CONCLUSIONS: This systematic review provided a precise summary of the clinical characteristics and treatment of patients presenting with Malignant breast myoepithelioma in the past 40 years. We anticipate that these results will help inform current investigations and treatment.


Subject(s)
Breast Neoplasms , Myoepithelioma , Humans , Adult , Middle Aged , Aged , Aged, 80 and over , Female , Breast Neoplasms/pathology , Mastectomy , Myoepithelioma/surgery , Mastectomy, Segmental , Axilla/pathology
3.
J Clin Med ; 11(20)2022 Oct 17.
Article in English | MEDLINE | ID: mdl-36294441

ABSTRACT

Objective: The aim of the present study was to evaluate evolution and prognosis of mucinous ovarian carcinomas (mOC), with respect to the two invasive patterns: expansile and infiltrative invasion. Methods: This was a descriptive, retrospective, multicenter study conducted in 13 French centres from 1 January 2001 to 31 December 2019. All patients operated on for epithelial ovarian neoplasia of the mucinous type (infiltrative/expansile) were included, whether the surgery was performed immediately or after neoadjuvant chemotherapy. Results: A total of 94 women with mucinous carcinomas were included in the present study. Mucinous tumours were divided into 35 expansile (37%) and 59 infiltrative (63%) mOC. There was a statistically significant difference in early and late stages at initial diagnosis between expansile and infiltrative mOC. None of the expansile mOC showed metastatic lymph nodes, whereas almost a quarter of the infiltrative mOC were metastatic to the pelvic/para-aortic region. There was a clear difference in RFS, in favour of expansile mOC, with 90% survival at 5 years, compared with 60% for infiltrative mOC. Conclusions: Although infiltrative and expansile mOC belong to the same histological family, they present many distinctions in clinical presentation, histological invasion, and disease course.

4.
J Clin Med ; 11(13)2022 Jun 23.
Article in English | MEDLINE | ID: mdl-35806930

ABSTRACT

INTRODUCTION: Borderline ovarian tumours (BOT) represent 10-20% of epithelial tumours of the ovary. Although their prognosis is excellent, the recurrence rate can be as high as 30%, and recurrence in the infiltrative form accounts for 3% to 5% of recurrences. Affecting, in one third of cases, women of childbearing age, the surgical strategy with ovarian conservation is now recommended despite a significant risk of recurrence. Few studies have focused exclusively on patients who have received ovarian conservative treatment in an attempt to identify factors predictive of recurrence and the impact on fertility. The objective of this study was to identify the risk factors for recurrence of BOT after conservative treatment and the impact on fertility. MATERIAL AND METHODS: This was a retrospective, multicentre study of women who received conservative surgery for BOT between February 1997 and September 2020. We divided the patients into two groups, the "R group" with recurrence and the "NR group" without recurrence. RESULTS: Of 175 patients included, 35 had a recurrence (R group, 20%) and 140 had no recurrence (NR group, 80%). With a mean follow-up of 30 months (IQ 8-62.5), the overall recurrence rate was 20%. Recurrence was BOT in 17.7% (31/175) and invasive in 2.3% (4/175). The mean time to recurrence was 29.5 months (IQ 16.5-52.5). Initial complete peritoneal staging (ICPS) was performed in 42.5% of patients (n = 75). In multivariate analysis, age at diagnosis, nulliparity, advanced FIGO stage, the presence of peritoneal implants, and the presence of a micropapillary component for serous tumours were factors influencing the occurrence of recurrence. The post-surgery fertility rate was 67%. CONCLUSION: This multicentre study is to date one of the largest studies analysing the risk factors for recurrence of BOT after conservative surgery. Five risk factors were found: age at diagnosis, nulliparity, advanced FIGO stage, the presence of implants, and a micropapillary component. Only 25% of the patients with recurrence underwent ICPS. These results reinforce the interest of initial peritoneal staging to avoid ignoring an advanced tumour stage.

5.
J Gynecol Obstet Hum Reprod ; 51(1): 102242, 2022 Jan.
Article in English | MEDLINE | ID: mdl-34715402

ABSTRACT

BACKGROUND: The aim of this study was to evaluate the impact of Lymphovascular Space Invasion (LVSI) on Overall Survival (OS) and Recurrence-Free Survival (RFS) in patients managed for high-grade serous epithelial ovarian cancer (HGSOC). MATERIALS AND METHODS: Retrospective multicenter study by the FRANCOGYN research group between January 2001 and December 2018. All patients managed for HGSOC and for whom histological slides for the review of LVSI were available, were included. The characteristics of patients with LVSI (LVSI group) were compared to those without LVSI (No LVSI group). A Cox analysis for OS and RFS analysis was performed in all populations. RESULTS: Over the study period, 410 patients were included in the thirteen institutions. Among them, 289 patients had LVSI (33.9%). LVSI was an independent predictive factor for poorer Overall and Recurrence-Free Survival. LVSI affected OS (p<0.001) and RFS (p<0.001), Association of LVSI status and estrogen receptor status (ER) also affected OS and RFS (p = 0.04; p = 0.04 respectively). CONCLUSION: The presence of LVSI in HGSOC has an impact on OS and RFS and should be routinely included in the pathology examination along with ER status.


Subject(s)
Ovarian Neoplasms/physiopathology , Receptors, Estrogen/classification , Adult , Aged , Aged, 80 and over , Female , France , Humans , Kaplan-Meier Estimate , Lymphatic Metastasis/pathology , Middle Aged , Ovarian Neoplasms/complications , Ovarian Neoplasms/pathology , Prognosis , Receptors, Estrogen/physiology , Retrospective Studies
6.
J Gynecol Obstet Hum Reprod ; 50(10): 102193, 2021 Dec.
Article in English | MEDLINE | ID: mdl-34224900

ABSTRACT

BACKGROUND: The aim of this study was to evaluate the impact of lymphovascular space invasion (LVSI) on overall survival (OS) and recurrence-free survival (RFS) in patients managed for stage I-IIa clear cell carcinoma, mucinous, low-grade serous and low-grade endometrioid ovarian cancer MATERIAL AND METHODS: Retrospective multicentre study of the research group FRANCOGYN between January 2001 and December 2018. All patients managed for stage I-IIa clear cell carcinoma, mucinous /low grade serous and endometrioid ovarian cancer and for whom the presence of histological slides for the review of LVSI was available, were included. Patient's characteristics with LVSI (LVSI group) were compared to those without LVSI (No LVSI group). A cox analysis for OS and RFS analysis were performed in all population. RESULTS: Over the study period, 133 patients were included in the thirteen institutions. Among them, 12 patients had LVSI (9%). LVSI was an independent predictive factor for poorer Overall and recurrence free survivals. LVSI affected OS (p < 0.001) and RFS (p = 0.0007), CONCLUSION: The presence of LVSI in stage I-IIa clear cell carcinoma, mucinous /low grade serous and endometrioid ovarian cancer has an impact on OS and RFS and should put them at high risk and consider the option of adjuvant chemotherapy.


Subject(s)
Chemotherapy, Adjuvant/methods , Decision Support Techniques , Endometrial Neoplasms/drug therapy , Neoplasm Metastasis , Ovarian Neoplasms/physiopathology , Adenocarcinoma, Clear Cell/drug therapy , Adenocarcinoma, Clear Cell/physiopathology , Adenocarcinoma, Mucinous/drug therapy , Adenocarcinoma, Mucinous/physiopathology , Adolescent , Adult , Aged , Aged, 80 and over , Chemotherapy, Adjuvant/statistics & numerical data , Endometrial Neoplasms/diagnosis , Endometrial Neoplasms/physiopathology , Female , France/epidemiology , Humans , Middle Aged , Neoplasm Staging/methods , Neoplasm Staging/statistics & numerical data , Ovarian Neoplasms/therapy , Retrospective Studies
7.
Arch Gynecol Obstet ; 304(6): 1577-1585, 2021 12.
Article in English | MEDLINE | ID: mdl-34184114

ABSTRACT

BACKGROUND: The presence of lymphovascular space invasion (LVSI) is not yet included in international recommendations neither as a prognostic factor nor as a parameter for the decision to use adjuvant chemotherapy in FIGO stage I/IIa ovarian cancer (OC). OBJECTIVE: This study set out to evaluate the impact of LVSI on Overall Survival (OS) and Recurrence-Free Survival (RFS) in patients managed for epithelial OC. DESIGN: Retrospective multicenter study by the research group FRANCOGYN between January 2001 and December 2018. All patients managed for epithelial OC surgery and for whom histological slides for the review of LVSI were available, were included. The characteristics of patients with LVSI (LVSI group) were compared to those without LVSI (No-LVSI group). A Cox analysis for OS and RFS analysis was performed in all the populations. SETTING: French multicenter tertiary care centers RESULTS: Over the study period, 852 patients were included in the 13 institutions. Among them, 289 patients had LVSI (33.9%). There was a significant difference in the distribution of LVSI between early and advanced stages (p < 0.001). LVSI was an independent predictive factor for poorer Overall and Recurrence-Free Survival. LVSI affected OS (p < 0.001) and RFS (p < 0.001), LVSI affected OS and RFS for early stages (p = 0.001; p = 0.001, respectively) and also for advanced stages (p = 0.01; p = 0.009, respectively). CONCLUSION: The presence of LVSI in epithelial ovarian epithelial tumors has an impact on OS and RFS and should be included in the routine pathology examination to adapt therapeutic management, especially for women in the early stages of the disease.


Subject(s)
Endometrial Neoplasms , Ovarian Neoplasms , Carcinoma, Ovarian Epithelial/therapy , Endometrial Neoplasms/pathology , Female , Humans , Lymphatic Metastasis , Neoplasm Invasiveness , Neoplasm Staging , Ovarian Neoplasms/pathology , Ovarian Neoplasms/therapy , Prognosis , Retrospective Studies
8.
Surg Oncol ; 38: 101597, 2021 Sep.
Article in English | MEDLINE | ID: mdl-34051659

ABSTRACT

In a previous pilot study, we showed that polyunsaturated n-3 fatty acids of breast adipose tissues were associated with breast cancer multifocality. In the present study, we investigated biochemical, clinical and histological factors associated with breast cancer focality in a large cohort of women with positive hormone-receptors tumors. One hundred sixty-one consecutive women presenting with positive hormone-receptors breast cancer underwent breast-imaging procedures including a Magnetic Resonance Imaging prior to treatment. Breast adipose tissue specimens were collected during surgery of tumors. A biochemical profile of breast adipose tissue fatty acids was established by gas chromatography. Clinicopathologic characteristics were correlated with multifocality. We assessed whether these factors were predictive of breast cancer focality. We found that tumor size (OR = 1.06 95%CI [1.02-1.09], p < 0.001) and decreased levels in breast adipose tissue of long-chain polyunsaturated n-3 fatty acids (OR = 0.11 95%CI [0.01-0.98], p = 0.03), were independent predictive factors of multifocality. Low levels of long chain polyunsaturated n-3 fatty acids in breast adipose tissue appear to contribute to breast cancer multifocality. The present results reinforce the link between dietary habits and breast cancer clinical presentation.


Subject(s)
Adipose Tissue/pathology , Breast Neoplasms/pathology , Fatty Acids, Omega-3/metabolism , Receptor, ErbB-2/metabolism , Receptors, Estrogen/metabolism , Receptors, Progesterone/metabolism , Adipose Tissue/metabolism , Adult , Aged , Aged, 80 and over , Breast Neoplasms/metabolism , Female , Follow-Up Studies , Humans , Middle Aged , Neoplasm Invasiveness , Prognosis
9.
J Gynecol Obstet Hum Reprod ; 50(6): 101877, 2021 Jun.
Article in English | MEDLINE | ID: mdl-32717332

ABSTRACT

We present the case of a young woman with abnormal vaginal bleeding two weeks after an abdominal myomectomy. The intervention was initially considered uncomplicated. Transvaginal sonography detected a pulsatile cystic area, just above the endometrium in the anterior wall of the lower uterine segment. Color Doppler analysis revealed the communication between an artery and a vein. Although, the ultrasound was completely sufficient for diagnosis, computed tomographic angiography was performed and confirmed the diagnosis of uterine pseudoanevrysm within the uterine myometrium. Selective arterial embolization was performed with complete recovery.


Subject(s)
Aneurysm, False/diagnostic imaging , Uterine Artery/diagnostic imaging , Uterine Myomectomy/adverse effects , Adult , Aneurysm, False/etiology , Aneurysm, False/therapy , Computed Tomography Angiography , Female , Humans , Ultrasonography, Doppler, Color , Uterine Artery Embolization , Uterine Hemorrhage/etiology , Uterine Hemorrhage/therapy
10.
J Gynecol Obstet Hum Reprod ; 50(2): 101928, 2021 Feb.
Article in English | MEDLINE | ID: mdl-33022450

ABSTRACT

CONTEXT: Hormone receptors (estrogen receptor ER and progesterone receptor PR) are prognostic and predictive factors of outcome for invasive breast cancer. Some tumors only express one of these hormone receptors (ER or PR). ER negative/PR positive breast cancer is a rare subtype (1-4 %) and its existence still controversial. The aim of this study was to evaluate characteristics of this group of tumors. METHODS: We collected data of all consecutive patients managed in our institution for invasive breast cancer between the 1st January 2007 and 31 December 2013. The aim of the study was to compare data of patients with ER-/PR+tumors with the three other subgroups. RESULTS: Of the 2071 patients included during the study period, 1.2 % were ER-/PR+. These patients were younger than those with the two ER+groups (p<0.0001). The ER-/PR+tumors differed from the ER+groups for several histological prognostic factors: greater histological size (p=0.0004), higher histological grade, more HER2 overexpression/amplification, more association with ductal carcinoma in situ, more lymphovascular invasion, more nodal metastasis (p<0.0001). Chemotherapy was more often used as an adjuvant treatment in addition of endocrine therapy. Survival was equivalent for patients with ER-/PR+tumors and ER+tumors and significantly higher than patients with ER-/PR- tumors (p<0.0001). CONCLUSION: Women with ER-/PR+breast cancer have worse prognostic factors than women with ER+cancers but have better overall survival than women with ER-/PR- tumors. We may think that the more frequent association of chemotherapy and endocrine therapy is responsible for this better outcome.


Subject(s)
Breast Neoplasms/metabolism , Receptors, Estrogen/metabolism , Receptors, Progesterone/metabolism , Adult , Aged , Aged, 80 and over , Breast Neoplasms/mortality , Breast Neoplasms/pathology , Breast Neoplasms/therapy , Carcinoma, Intraductal, Noninfiltrating/pathology , Chemotherapy, Adjuvant , Estrogen Antagonists/therapeutic use , Female , Humans , Lymphatic Metastasis , Middle Aged , Neoplasm Invasiveness , Prognosis , Receptor, ErbB-2/metabolism , Retrospective Studies , Young Adult
11.
Nutrients ; 12(12)2020 Dec 15.
Article in English | MEDLINE | ID: mdl-33333962

ABSTRACT

In the present study, we investigated various biochemical, clinical, and histological factors associated with bone metastases in a large cohort of pre- and postmenopausal women with breast cancer. Two hundred and sixty-one consecutive women with breast cancer were included in this study. Breast adipose tissue specimens were collected during surgery. After having established the fatty acid profile of breast adipose tissue by gas chromatography, we determined whether there were differences associated with the occurrence of bone metastases in these patients. Regarding the clinical and histological criteria, a majority of the patients with bone metastases (around 70%) had tumors with a luminal phenotype and 59% of them showed axillary lymph node involvement. Moreover, we found a negative association between the levels of n-3 long-chain polyunsaturated fatty acids (LC-PUFA) in breast adipose tissue and the development of bone metastases in premenopausal women. No significant association was observed in postmenopausal women. In addition to a luminal phenotype and axillary lymph node involvement, low levels of n-3 LC-PUFA in breast adipose tissue may constitute a risk factor that contributes to breast cancer bone metastases formation in premenopausal women.


Subject(s)
Adipose Tissue/metabolism , Bone Neoplasms/secondary , Breast Neoplasms/pathology , Fatty Acids, Omega-3/metabolism , Premenopause/metabolism , Adult , Aged , Aged, 80 and over , Breast/metabolism , Breast/pathology , Breast Neoplasms/metabolism , Chromatography, Gas , Female , Humans , Middle Aged , Neoplasm Metastasis , Phenotype , Postmenopause/metabolism , Retrospective Studies , Risk Factors
12.
J Gynecol Obstet Hum Reprod ; 49(9): 101867, 2020 Nov.
Article in English | MEDLINE | ID: mdl-32663654

ABSTRACT

INTRODUCTION: Peritoneal carcinomatosis extent in ovarian cancer is difficult to evaluate by imaging techniques even though it determines the surgical complexity and survival. The aim of this study was to estimate the accuracy of 2-[18F]-fluoro-2-deoxy-d-glucose (FDG)-PET CT (Positron-emission tomography coupled with Computerised Tomography) performed before any treatment, in the diagnosis of the extent of peritoneal carcinomatosis. We compared these results to per-operative observations/ histology samples obtained during surgery (laparotomy/ laparoscopy). MATERIAL AND METHODS: All women managed for an epithelial ovarian cancer between 1st January 2000 and 30th June 2016 were included if they had a FDG PET CT, before initiation of any treatment (neoadjuvant chemotherapy or frontline cytoreductive surgery). The extent of disease on histology samples from cytoreductive surgery/observations during exploratory laparoscopy were compared with the PET CT results. RESULTS: Over the study period, 980 women were managed for epithelial ovarian cancer, among them 90 (9.2 %) had a PET CT before any treatment. The diagnostic reliability of an ovarian lesion was 67.8 %, a colon lesion was 61.25 %, a small intestine lesion was 50.6 %, an epiploic lesion was 41.7 %, a pelvic ganglionic invasion was 62.9 % and a paraortic lymph node invasion was 61.5 %. PET CT was less effective than a standard CT examination. CONCLUSION: PET CT is not the most effective imaging examination to estimate the extent of peritoneal carcinomatosis during the initial management of an epithelial ovarian cancer.


Subject(s)
Carcinoma, Ovarian Epithelial/pathology , Carcinoma/diagnostic imaging , Ovarian Neoplasms/pathology , Peritoneal Neoplasms/diagnostic imaging , Positron Emission Tomography Computed Tomography/statistics & numerical data , Adult , Aged , Aged, 80 and over , CA-125 Antigen/blood , Carcinoma/pathology , Carcinoma, Ovarian Epithelial/therapy , Female , Fluorodeoxyglucose F18 , France , Humans , Middle Aged , Neoplasm Metastasis/pathology , Neoplasm Staging , Ovarian Neoplasms/therapy , Peritoneal Neoplasms/pathology , Radiopharmaceuticals , Sensitivity and Specificity , Survival Rate
13.
Eur J Obstet Gynecol Reprod Biol ; 251: 14-19, 2020 Aug.
Article in English | MEDLINE | ID: mdl-32502770

ABSTRACT

OBJECTIVE: To identify factors predictive of high discordance (>20 mm) between lesion sizes measured by magnetic resonance imaging (MRI) and histology for invasive lobular breast cancer. MATERIALS AND METHODS: Data for all women with invasive lobular breast cancer (pure or associated with a component of invasive ductal carcinoma) between 1st January 2007 and 31st December 2016 were included in this study. Logistic regression analysis was performed to determine factors predictive of high discordance (underestimation/overestimation by >20 mm) between tumour sizes measured by MRI and histology for invasive lobular breast cancer. RESULTS: For overestimation, significant factors on univariate analysis were: menopausal status [odds ratio (OR) 0.27, 95 % confidence interval (CI) 0.10-0.71]; p = 0.01], hormone receptor (HR) status (HR negative, OR 1.64, 95 % CI 0.27-9.89; HR positive, OR 0.64, 95 % CI 0.21-1.88; p = 0.09) and neoadjuvant chemotherapy (OR 10.33, 95 % CI 3.58-29.8; p < 0.001). On multivariate analysis, menopausal status and neoadjuvant chemotherapy were found to be independent predictive factors of overestimation. For underestimation, significant factors on univariate analysis were: histological size (OR 1.05, 95 % CI 1.02-1.08; p < 0.0001) and the presence of an in-situ component (OR 4.66, 95 % CI 1.01-21.5; p = 0.02). These two factors were independent predictive factors of underestimation. CONCLUSION: Independent predictive factors of overestimation/underestimation (threshold 20 mm) of tumour sizes measured by MRI compared with histology for invasive lobular breast cancer were identified.


Subject(s)
Breast Neoplasms , Carcinoma, Ductal, Breast , Carcinoma, Lobular , Breast Neoplasms/diagnostic imaging , Carcinoma, Ductal, Breast/diagnostic imaging , Carcinoma, Lobular/diagnostic imaging , Female , Humans , Magnetic Resonance Imaging , Neoadjuvant Therapy
14.
Eur J Obstet Gynecol Reprod Biol ; 249: 64-69, 2020 Jun.
Article in English | MEDLINE | ID: mdl-32381349

ABSTRACT

INTRODUCTION: The aim of this study was to compare overall survival (OS) between women with isolated lymph node recurrence (ILNR) and those with isolated peritoneal localization of recurrence (ICR), in patients managed for epithelial ovarian cancer. METHODS: Data from 1508 patients with ovarian cancer were collected retrospectively from1 January 2000 to 31 December 2016, from the FRANCOGYN database, pooling data from 11 centres specialized in ovary treatment. Median overall survival was determined using the Kaplan-Meier method. Univariate and multivariate analyses were performed to define prognostic factors of overall survival. Patients included had a first recurrence defined as ILNR or ICR during their follow up. RESULTS: 79 patients (5.2 %) presented with ILNR, and 247 (16.4 %) patients had isolated carcinomatosis recurrence. Complete lymphadenectomy was performed more frequently in the ILNR group vs. the ICR group (67.1 % vs. 53.4 %, p = 0.004) and the number of pelvic lymph nodes involved was higher (2.4 vs. 1.1, p = 0.008). The number of involved pelvic LN was an independent predictor of ILNR (OR = 1.231, 95 % CI [1.074-1.412], p = 0.0024). The 3-year and 5-year OS rates in the ILNR group were 85.2 % and 53.7 % respectively, compared to 68.1 % and 46.8 % in patients with ICR. There was no significant difference in terms of OS after initial diagnosis (p = 0.18). 3- year and 5-year OS rates after diagnosis of recurrence were 62.6 % and 15.6 % in the ILNR group, and 44 % and 15.7 % in patients with ICR (p = 0.21). CONCLUSION: ILNR does not seem to be associated with a better prognosis in terms of OS.


Subject(s)
Carcinoma, Ovarian Epithelial/mortality , Lymph Node Excision/mortality , Neoplasm Recurrence, Local/mortality , Ovarian Neoplasms/mortality , Adult , Aged , Aged, 80 and over , Carcinoma, Ovarian Epithelial/pathology , Databases, Factual , Female , Humans , Kaplan-Meier Estimate , Lymph Nodes/pathology , Lymphatic Metastasis , Middle Aged , Neoplasm Recurrence, Local/pathology , Ovarian Neoplasms/pathology , Prognosis , Retrospective Studies , Survival Rate , Young Adult
15.
Eur J Obstet Gynecol Reprod Biol ; 244: 66-70, 2020 Jan.
Article in English | MEDLINE | ID: mdl-31760264

ABSTRACT

PURPOSE: In the present study, we present a large institutional study to determine the influence of age≥ 80 years on breast cancer presentation and prognosis. METHODS: The study is a retrospective analysis of our prospectively maintained breast cancer database study using data from of women managed from January 2007 through December 2013. Clinicopathologic characteristics were correlated with outcomes according to age (<80 years and ≥ 80 years). RESULTS: During the study period, 2083 women with invasive breast cancer were included of which 160 women aged ≥ 80 years (7.7 %). Overall survival was lower in the oldest old than in younger counterparts (p < 0.0001) as was distant metastasis free survival (p = 0.004). Differences in management included more radical surgeries and less chemotherapy and radiotherapy in case of age≥ 80 years. By multivariate analysis, age ≥ 80 years was an independent predictive factor of poor overall survival. CONCLUSION: In the present study, age ≥ 80 years was an independent predictive factor of poor overall survival.


Subject(s)
Breast Neoplasms/mortality , Carcinoma, Ductal, Breast/mortality , Carcinoma, Lobular/mortality , Adult , Aged , Aged, 80 and over , Breast Neoplasms/therapy , Carcinoma, Ductal, Breast/therapy , Carcinoma, Lobular/therapy , France/epidemiology , Humans , Middle Aged , Retrospective Studies , Young Adult
16.
Acta Oncol ; 59(5): 518-524, 2020 May.
Article in English | MEDLINE | ID: mdl-31718368

ABSTRACT

Background and objectives: The aim was to review the clinical impact of groin metastatic nodal disease in women with vulvar squamous cell carcinoma (VSCC) and to evaluate the impact of adjuvant radiotherapy on women with single intracapsular lymph node metastasis (SILNM).Methods: Cohort study of women with vulvar squamous cell carcinoma (VSCC) managed between January 2005 and December 2015 in five institutions in France with prospectively maintained databases (French multicentre tertiary care centres). We evaluated Impact of SILNM on outcome.Results: A total of 176 women (34.6%) had at least one positive lymph node (LN). There were no significant differences for the 5-year overall survival rates between women with one extracapsular LN metastasis and women with one intracapsular LN metastasis, or with two node metastases (p = .62, p = .63 respectively). In women with a SILNM: (1) lymphovascular invasion (LVSI) was an independent negative predictive factor recurrence-free survival (RFS) (HR = 0.10 (95%CI, 0.01-0.90), p = .04) and (2) Adjuvant inguino-femoral radiotherapy was a positive independent factor associated with RFS (HR = 5.87 (95%CI 1.21-28.5), p = .02).Conclusion: A potential positive effect of adjuvant radiotherapy in node positive VSCC, irrespective of the number of affected LN, should be considered especially in the case of LVSI.


Subject(s)
Carcinoma, Squamous Cell/therapy , Lymphatic Metastasis/therapy , Neoplasm Recurrence, Local/epidemiology , Vulvar Neoplasms/therapy , Adult , Aged , Aged, 80 and over , Carcinoma, Squamous Cell/mortality , Carcinoma, Squamous Cell/secondary , Disease-Free Survival , Female , Follow-Up Studies , France/epidemiology , Groin , Humans , Lymph Node Excision , Lymph Nodes/pathology , Lymph Nodes/radiation effects , Lymph Nodes/surgery , Middle Aged , Neoplasm Invasiveness/pathology , Neoplasm Recurrence, Local/pathology , Neoplasm Recurrence, Local/prevention & control , Neoplasm Staging , Prognosis , Prospective Studies , Radiotherapy, Adjuvant/methods , Retrospective Studies , Risk Factors , Survival Rate , Vulva/pathology , Vulva/radiation effects , Vulva/surgery , Vulvar Neoplasms/mortality , Vulvar Neoplasms/pathology , Young Adult
17.
Breast J ; 25(4): 696-701, 2019 07.
Article in English | MEDLINE | ID: mdl-31066151

ABSTRACT

We developed a risk scoring system (RSS) for predicting breast conservative surgery (BCS) in women receiving neoadjuvant chemotherapy(NAC) for breast cancer. BCS rate in the training set was 32.6%, associated with five variables: age < 50years, primary radiological tumor diameter < 60mm, absence of multifocality, absence of breast inflammation and hormone receptor status. These variables were assigned scores ranging from 0 to 9. The discrimination of the RSS was 0.78(95%CI 0.69-0.86) in the training set. The area under the curve of the receiver operating characteristics for predicting BCS after internal and external validation was 0.77(95%CI 0.68-0.85) and 0.75(95%CI 0.66-0.84), respectively.


Subject(s)
Breast Neoplasms/drug therapy , Breast Neoplasms/surgery , Mastectomy, Segmental , Adult , Aged , Aged, 80 and over , Area Under Curve , Breast Neoplasms/mortality , Breast Neoplasms/pathology , Female , Humans , Logistic Models , Middle Aged , Neoadjuvant Therapy , Neoplasm Recurrence, Local , Patient Selection , Reproducibility of Results , Risk Assessment/methods , Young Adult
18.
J Gynecol Obstet Hum Reprod ; 48(7): 489-494, 2019 Sep.
Article in English | MEDLINE | ID: mdl-30986541

ABSTRACT

OBJECTIVES: The aim of our work was to investigate changes in presentation and endometrial cancer (EC) types frequencies thorough a 40 years study period. PATIENTS AND METHODS: The patient group consisted of consecutive women undergoing surgery for endometrial cancer in our institution between 1975, and 2014. Clinical data included age, BMI (Kg/m2), histological data from surgical staging and survival data. RESULTS: 842 patients with the final diagnosis of endometrial cancer were enrolled. BMI was overweight rising through study decades. Age of diagnosis was also in constant augmentation since 1975. Type II EC proportion was 9.2% in the seventies and 27.9% after 2000. Overall survival was stable over time. Women with BMI < 18 kg/m2 had lower overall survival when compared to women with other BMI categories (p < 0.0001). DISCUSSION AND CONCLUSION: An analysis on a larger population of underweight women with EC is needed to identify specific factors. A trend to develop more type II EC can partly explain these results. We identified a clear trend of augmentation of type II EC, known to have a poor prognosis while necessitating specific surgical management. Histologic analysis standardisation, surgical strategy and amelioration of adjuvant treatments permitted to maintain a stable overall survival for the whole population despite this augmentation.


Subject(s)
Carcinoma, Endometrioid/epidemiology , Endometrial Neoplasms/epidemiology , Gynecology/trends , Medical Oncology/trends , Adult , Aged , Aged, 80 and over , Cancer Care Facilities/statistics & numerical data , Carcinoma, Endometrioid/mortality , Carcinoma, Endometrioid/pathology , Endometrial Neoplasms/mortality , Endometrial Neoplasms/pathology , Female , France/epidemiology , Gynecology/statistics & numerical data , Humans , Medical Oncology/statistics & numerical data , Middle Aged , Registries/statistics & numerical data , Retrospective Studies , Survival Analysis , Tertiary Care Centers/statistics & numerical data
19.
Presse Med ; 48(4): 376-383, 2019 Apr.
Article in French | MEDLINE | ID: mdl-30926206

ABSTRACT

Pregnancies after breast cancer are still relatively rare observations. It was considered for a long time that a woman previously treated for a breast cancer could favour recurrence by becoming pregnant because of the hormonal impregnation. However, the improvement of the breast cancer treatments thanks to the improvement of the knowledge on this disease, allowed these women to envisage pregnancies after this disease. The current recommendations do not dissuade the pregnancy in case of complete cure. However, a pregnancy in this particular context arouses a number of questions such as the delay between the cancer and the pregnancy, the progress of these pregnancies, the oncologic and obstetric follow-up, the breast-feeding and its impact on breast cancer prognosis. The aim of this work is to answer these questions through a literature review.


Subject(s)
Breast Neoplasms , Pregnancy Outcome , Antineoplastic Agents/adverse effects , Breast Neoplasms/therapy , Female , Humans , Pregnancy , Pregnancy Complications/etiology , Risk Factors
20.
Eur J Surg Oncol ; 45(4): 672-678, 2019 04.
Article in English | MEDLINE | ID: mdl-30722948

ABSTRACT

Patterns of distant metastatic failure of endometrial cancer (EC) by specific anatomic site are not well described in the literature. In this manuscript, we evaluated the metastatic patterns of EC cancer and analysed the potential distribution of metastatic disease in this malignancy. METHODS: A total of 1444 women with EC were identified. Of which we extracted women with locoregional and distant recurrence or with distant recurrence alone. Women were scored based on first site of metastasis: multiple versus one site: bone, brain, lung, liver or sus diaphragmatic lymph nodes. RESULTS: 110 women developed distant metastatic disease with (n = 37(33.6%)) or without (n = 73(66.4%)) locoregional recurrence, including 39 women with exclusive first site of metastatic disease and 34 women with multiple sites of metastatic disease. When considering all women, the most common exclusive first site of metastasis was lung (42.8%). The median time to develop distant metastases was shorter after the completion of treatment for exclusive brain metastatic disease compared with other sites of metastatic- disease (7 months vs, 9 for lung, 10 for liver, 19 for bone and 27 months for sus-diaphragmatic LN; P = 0.004). The rate of 3-year overall survival was higher in the sus-diaphragmatic LN metastase group (83.3% vs 50.6% for lung, 37.3% for bone, 16.7% for brain and 0% for liver; P = 0.0059). CONCLUSION: The present study has demonstrated the site-specific patterns of metastases. These data support current clinical practice of screening for site-specific metastatic disease after initial treatment of early stage EC based on concerning women-specific signs or symptoms.


Subject(s)
Bone Neoplasms/secondary , Brain Neoplasms/secondary , Endometrial Neoplasms/pathology , Endometrial Neoplasms/surgery , Liver Neoplasms/secondary , Lung Neoplasms/secondary , Neoplasm Recurrence, Local/pathology , Aged , Aged, 80 and over , Diaphragm , Disease-Free Survival , Female , France , Humans , Lymph Nodes/pathology , Lymphatic Metastasis , Middle Aged , Neoplasm Staging , Survival Rate
SELECTION OF CITATIONS
SEARCH DETAIL